Status:
RECRUITING
A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions:
PFO - Patent Foramen Ovale
Migraine
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Migraine is one of the most common chronic neurological disorders, posing a significant global public health concern. Patent Foramen Ovale (PFO) is the most common congenital heart anomaly in adults. ...
Eligibility Criteria
Inclusion
- Age 18-65
- Diagnosed migraine by ICHD-3
- History of migraine longer than 1 year, and symptoms severely disturbing daily life.
- TCD/TTE/TEE diagnosed patent foramen ovale with right to left shunt
- Willing to participant and agree to follow-ups
- Received at least three different types of migraine preventive drugs, the responder rate of previous therapy did not receive 50%.
Exclusion
- Migraine caused by other reason
- Had TIA/stroke history
- With contraindication or hypersensitive to anti-platelet or anticoagulation drugs.
- With contraindication to PFO occlusion
Key Trial Info
Start Date :
March 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06203873
Start Date
March 1 2024
End Date
March 1 2026
Last Update
December 4 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuwai Hospital
Beijing, Beijing Municipality, China, 100037
2
Fuwai Hospital
Beijing, Beijing Municipality, China, 100037